For what seems the longest time, we have seen the battle in metastatic clear cell renal cell carcinoma (ccRCC) being focused on various anti-VEGF TKIs, whether against interferon, mTOR inhibitors, and even each other.
Lately, anti-PD(L)1 antibodies have also come on the scene – both as monotherapy and in different combinations – so are things set to change?
Will it be plaining sailing or are there hidden dangers ahead for the unwary?
Here, we take a look at the ever evolving landscape in RCC and explore the issues and challenges surrounding some of the novel combination readouts, including a look at the role immuno-oncology might play going forward.
Not surprisingly, there’s a lot to consider, discuss and think about…
To learn more and get a heads up on our latest conference and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
At the 2018 ASCO Genitourinary Cancer Symposium, one of the standout keynote lectures was from Professor Tom Powles, Director of the Bart’s Cancer Cancer Center in London who talked about “Immune checkpoint inhibitors in Urothelial Cancer: which one and why?”
We’ve been following the highs and lows around checkpoint inhibitors in bladder cancer for some time, so it was interesting to hear what Prof Powles had to say in San Francisco.
How does he see the landscape evolving for immune checkpoint inhibitors?
To learn more and get a heads up on our latest oncology and conference insights, subscribers can log-in or you can click to gain access to BSB Premium Content.